Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QYJD Compound Preparation is a traditional Chinese medicine (TCM) formulation developed by Fuzhou General Hospital, specifically designed to facilitate rapid postoperative recovery in patients with early-stage non-small cell lung cancer (NSCLC). The preparation is characterized by its therapeutic properties of clearing heat, removing toxins, dispelling blood stasis, and relieving pain. It is administered orally following thoracoscopic radical surgery. Clinical research focuses on its ability to regulate the lung tissue microecology (microbiome), which is assessed using metagenomics next-generation sequencing (mNGS) to understand its role in promoting rehabilitation and potentially improving long-term outcomes for NSCLC patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on QYJD Compound Preparation.